GlycoErase™ ALG9 Knockout Human Bladder Cancer Cell 5637 (CAT#: GLJF-0525-JF6)

Description	human bladder bancer bell line 5637 with ablated ALG9 expression provides a valuable tool for the examination of lipid-linked oligosaccharide assembly aberrations within the context of bladder carcinoma; the absence of functional ALG9 perturbs the N-glycosylation machinery, prompting researchers to explore the associations between N-glycosylation irregularities and various facets of bladder cancer, including its development, advancement, metastatic potential, and to investigate therapeutic strategies centered on ALG9.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:3~1:6
Cell Line	5637
Primary Disease	Bladder Urothelial Carcinoma
Lineage	Bladder/Urinary Tract

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	FBS & Penicillin/Streptomycin & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	ALG9
Full Name	ALG9 alpha-1,2-mannosyltransferase
Alternative Name	DIBD1
Location	11q23.1
Gene ID	79796
Summary	Facilitates lipid-linked oligosaccharide assembly; mutations lead to CDG II (congenital disorder of glycosylation type II); multiple transcript variants (different isoforms) may influence enzyme specificity.